KG
Kenneth Galbraith (Chair & CEO) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Zymeworks Inc. (ZYME). The largest single filing was $1.4M of ZYME (54,343 sh across 2 lots, as filed), executed Jan 5. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.3M
shares × price, as filed
Last traded
Jan 12
Filed Jan 12
Median ADV $18.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $4.2M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
ZYME
Zymeworks Inc.
ZYME · 0 buys · 4 sells
4 filings
Recent filings
ZYMESALE
Zymeworks Inc.
View filing →
$690K30,424 sh × $22.67
Exec Jan 12
Filed Jan 12 · 5:30 PM ET ZYMESALE Zymeworks Inc. View filing → $1.4M
54,343 sh across 2 lots
Exec Jan 5
Filed Jan 5 · 5:30 PM ET ZYMESALE Zymeworks Inc. View filing → $1.3M
47,528 sh × $27.02
Exec Dec 22 2025
Filed Dec 22 2025 · 5:30 PM ET ZYMESALE Zymeworks Inc. View filing → $855K
57,291 sh across 2 lots
Exec Jan 6 2025
Filed Jan 6 2025 · 5:30 PM ET